The U.S. District Court for the Northern District of Mississippi has entered a consent decree prohibiting Delta Pharma from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and FDA regulations, the Food and Drug Administration announced Friday. The company is registered as an outsourcing facility under Section 503B of the Act. "That legislation envisioned an important role for outsourcing facilities to help supply providers with compounded medicines, but it also required that these firms meet good manufacturing practice requirements,” said FDA Commissioner Scott Gottlieb, M.D. “When we find outsourcing facilities that continue to violate the law by not adhering to these manufacturing requirements, and put patients at risk, we’re going to hold them accountable under the law. At the same time, we’re also pursuing new policy steps to help make it more feasible for compounders to meet the requirements of becoming an outsourcing facility.”

Related News Articles

Headline
The Senate Committee on Health, Education, Labor and Pensions today held a hearing on the Lower Health Care Costs Act, its draft legislation to prevent…
Headline
AHA said it generally supports the reforms to update the payment system, but expressed concern with the substantial redistribution of cases under the payment…
Headline
The departments of Labor, Health and Human Services, and the Treasury yesterday finalized a rule that will allow employers to use health reimbursement…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The AHA today voiced support for legislation to revise and extend federal programs to develop the nursing workforce.
Headline
The AHA today submitted comments to the Senate Health, Education, Labor and Pensions Committee on their bipartisan discussion draft legislation, the Lower…